Reuters: Regulatory News: AstraZeneca looks for new heart drug approval by next May

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Refresh your vocabulary. Learn a new word everyday by subscribing to Word of the Day. A great tool if you're studying for the GRE, GMAT or LSAT, or simply want to enhance your lexicon. From our sponsors

AstraZeneca looks for new heart drug approval by next May Sep 18th 2013, 06:36 LONDON, Sept 18 | Wed Sep 18, 2013 2:36am EDT LONDON, Sept 18 (Reuters) - U.S. regulators have accepted an experimental fish oil-based heart drug from AstraZeneca for review and will make a decision on whether to approve it by next May. Epanova, for treating people with very high levels of fatty triglycerides in their blood, was developed by Omthera Pharmaceuticals, which AstraZeneca acquired earlier this year. AstraZeneca said on Wednesday that the U.S. Food and Drug Administration had set a date of May 5, 2014 to act on the Epanova submission. Buying Omthera forms part of a drive by Chief Executive Pascal Soriot to revive AstraZeneca's fortunes through a series of bolt-on deals in core areas, including cardiovascular medicine. The acquisition pitches AstraZeneca into competition with rivals including GlaxoSmithKline and Amarin that already have similar heart-friendly fish oil drugs approved. AstraZeneca's sales and profits are falling as older medicines lose patent protection and the company badly needs new products to replace former big sellers like the antipsychotic Seroquel, which lost exclusivity last year. Cardiovascular medicine is a key area for AstraZeneca, whose top-selling drug is the cholesterol fighter Crestor. The British-based group is working on a fixed-dose combination of Crestor and Epanova that, if successful, would extend the Crestor franchise beyond 2016, when the drug's U.S. patent ends. AstraZeneca is also banking on another heart drug, Brilinta, to drive sales, although this product has so far been slow to take off. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions